The road from discovery to clinic: adiponectin as a biomarker of metabolic status.
Biomarkers are globally used to monitor clinical responses to therapeutic and lifestyle interventions. The adipocyte-derived hormone adiponectin is recognized as a promising new biomarker owing to its many associations with components of the metabolic syndrome. The study described by Wagner and colleagues in this issue offers a first example of how a large-scale effort in the context of a cross-company collaborative study in the pharmaceutical industry can offer a powerful tool for the further validation of a new biomarker in the context of pharmacological intervention with peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists.
Kusminski
C M
CM
Touchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Scherer
P E
PE
D052242:Adiponectin / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D013997:Time Factors; D057170:Translational Research, Biomedical; D016896:Treatment Outcome
D052242:Adiponectin; D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D047492:Peroxisome Proliferator-Activated Receptors; C499918:ADIPOQ protein, human; C517652:hemoglobin A1c protein, human